HCPLive Network

Immunogenicity Strongly Impacts Response to Adalimumab in Rheumatoid Arthritis

 
THURSDAY, Dec. 13 (HealthDay News) -- For patients with rheumatoid arthritis (RA), long-term clinical outcomes are good with etanercept and adalimumab; but for adalimumab, treatment response is strongly dependent on the presence or absence of anti-adalimumab antibodies, according to research published in the December issue of Arthritis & Rheumatism.

Charlotte L. Krieckaert, M.D., of the Jan van Breemen Research Institute in Amsterdam, and colleagues conducted a study involving 407 patients with RA who were naive to tumor necrosis factor antagonists and received either etanercept (203 patients) or adalimumab (204 patients).

The researchers found that, of the adalimumab group, 13, 15, and 16 percent, respectively, reached sustained low disease activity, sustained minimal disease activity, and sustained American College of Rheumatology/European League Against Rheumatism remission. The corresponding rates were 16, 11, and 12 percent in the etanercept group. The best outcomes were seen for adalimumab-treated patients without anti-adalimumab antibodies; the worst outcomes were seen for those with anti-adalimumab antibodies; and intermediate outcomes were seen for etanercept-treated patients. At least sustained minimal disease activity was seen for 40 percent of patients without anti-adalimumab antibodies; 23 percent of etanercept-treated patients; and 4 percent of patients with anti-adalimumab antibodies.

"Overall, etanercept and adalimumab treatment appear similar in inducing a good long-term clinical outcome," the authors write. "However, in the case of adalimumab this is strongly dependent on the presence or absence of anti-adalimumab antibodies."

Several authors disclosed financial ties to pharmaceutical companies, including Pfizer (Wyeth) and Abbott Laboratories, both of which partially funded the study.
 

Abstract
Full Text (subscription or payment may be required)

 
Copyright © 2012 HealthDay. All rights reserved.
 
 
 

Further Reading
Study results show that eluxadoline may be useful in patients with diarrhea-predominant irritable bowel syndrome (IBS-D) who do not achieve symptom relief with loperamide.
Study results show significant regional variations in the types of procedures and tests administered and the number of prescriptions written for patients with irritable bowel syndrome (IBS), as well as in the number of emergency department visits and hospital admissions.
John Saltzman, MD, Discusses the gastrointestinal tract and its part in the functioning of the body.
Type 2 diabetes occurs at roughly the same prevalence in men and women. Despite the similar prevalence in the sexes, women who develop diabetes feel the effect of its complications disproportionately.
Research presented at the European League Against Rheumatism’s Annual Meeting indicates comorbid diabetes may be linked to increased osteoarthritis pain.
Analysis of a dozen phase III trials indicates that patients with atrial fibrillation face significantly less risk of major, fatal, and intracranial bleeding if they take target-specific oral anticoagulants rather than vitamin K antagonists.
Calculation and interpretation of the anion gap is extremely useful in the evaluation and treatment of the patient with metabolic acidosis. In this installment, we look at case examples involving patients with multiple sclerosis and urosepsis; COPD, diabetes, and renal failure; and type 1 diabetes.
More Reading